Introduction: Commonly reported complications after concurrent chemoradiotherapy
Introduction
Concurrent chemoradiotherapy (CCRT) is considered to be the standard of care for fit patients who present with a stage III non-small-cell lung cancer (NSCLC). 1 The survival gains observed with CCRT relative to the sequential administration of both modalities have been attributed to improved loco-regional tumor control. 2 Increased toxicity observed with CCRT includes acute esophagitis and neutropenia, with grade III/IV neutropenia reported in range of 32% to 43% of patients treated using cisplatin-etoposide and concurrent radiotherapy. [3] [4] [5] A retrospective analysis of late complications after CCRT to 66 Gy or higher, reported pulmonary complications including bronchial stenosis and fatal hemoptysis but neither tumor cavitation nor fatal infections were mentioned. 6 About 10% to 20% of all lung carcinomas present with radiological cavitation, which is believed to be due to tumor necrosis as a consequence of ischaemia and/or bronchial obstruction. 7 Earlier reports had observed that cavitated tumors undergoing treatment with chemotherapy and/or radiotherapy could result in potentially "serious, difficult-to-treat infectious complications." 8, 9 Awareness of tumor cavitation has increased since this finding was linked to the toxicity and efficacy of antiangiogenic agents in NSCLC. 10, 11 CCRT has been our routine treatment strategy for stage III NSCLC since 2003. 12 After encountering isolated cases of cavitation developing in such, we evaluated the incidence, All diagnostic and radiotherapy planning computed tomography (CT) scans before the start of CCRT were reviewed by two authors (EP and SS) for tumor cavitation, which was defined as an air-containing cavity within the primary tumor and which was not identifiable as an airway. At the time these patients were treated, the institutional policy was not influenced by the presence of cavities in the tumor. Subsequently, patient/treatment characteristics, details of pulmonary toxicity of grade III or more (National Cancer Institute Common Toxicity Criteria v3.0) within 90 days after the end of radiotherapy, and follow-up data were derived from an institutional database. Progression-free and overall survival was calculated using the Kaplan-Meier method and calculated from start of chemotherapy to September 2, 2011.
Results are presented as median and range or number and percentage. A p value less than 0.05 was considered statistically significant.
Results

Incidence of tumor cavitation and survival
Characteristics of the 87 eligible patients are summarized in Table 1 . Sixteen patients (18%) had a cavity in the primary tumor before the start of CCRT, with maximal cavity diameters ranging between 0.5 and 4.5 cm. In this patient group, the histology was squamous cell carcinoma (SCC) (n = 14), adenocarcinoma (n = 1), or large-cell undifferentiated carcinoma 
Pulmonary toxicity of grade III or more, and follow-up of patients
Eight of 16 patients (50%) with pretreatment tumor cavitation developed acute pulmonary toxicity of grade III or more, other than radiation pneumonitis, as opposed to only 12 of 71 (17%) in those without tumor cavitation. Table 2 summarizes details of all 20 patients developing acute pulmonary toxicity of grade III or more. Two patients with large cavitated tumors died of massive pulmonary hemorrhage 1 month after start of the treatment. Another patient died 2 weeks after the end of radiotherapy (46 Gy) from pulmonary embolism.
Infection, presenting as an air-fluid level in the tumor cavitation (tumor abscess) on radiological imaging, was observed in the five remaining patients. Of these, one patient was hospitalized and treated with intravenous (IV) administration of antibiotics during CCRT, but died shortly after treatment. The other four were hospitalized 10, 13, 21, and 87 days, respectively, after the end of radiation treatment. Of the latter, two patients recovered after IV administration of antibiotics, and subsequently developed intrathoracic disease progression after 18.5 and 27 months. T4NxM0 IIIB  T3N2M0 IIIA  T4NxM0 IIIB  T3N2M0 IIIA  TxN3M0 IIIB  T4NxM0 IIIB  T4N2M0 IIIB  T4NxM0 IIIB  T4N3M0 IIIB  T4N2M0 IIIB  T4N2M0 IIIB  T4NxM0 IIIB  T2N2M0 IIIA  T2N2M0 IIIA  T4N2M0 IIIB  T4N3M0 IIIB  T2N2M0 IIIA  T4NxM0 IIIB  T4NxM0 IIIB  T2N2M0 IIIA   Table 2 . Characteristics of patients with grade ≥III acute pulmonary toxicity (n=20) Sex
TNM, tumor-node-metastasis; WBC toxicity, leucocytopenia; SCC, squamous-cell carcinoma; Large-cell, large-cell undifferentiated carcinoma; Adeno, adenocarcinoma; CCRT, concurrent chemoradiotherapy; TO-fistula, trachea-oesophageal fistula. To the best of our knowledge, no previous reports have highlighted such a high incidence of complications related to tumor cavitation during or after CCRT in phase III trials or recent meta-analyses. [2] [3] [4] [5] 14 Publications of randomized clinical trials may have failed to identify some clinical toxicities, as a result of patient selection and insufficient follow-up. 15 In addition, regional differences in the incidence of squamous-cell tumors may also have contributed to under-reporting. For example, only 33% of patients in a large phase III CCRT trial from the United States had SCC, 4 whereas 43% of patients in the present study had SCC. In the Netherlands, the proportion of non-SCCs increased between the periods 1989 to 1993 and 2004 to 2009, from 42% to 67% for male patients and from 67% to 81% for female patients. 16 Yet another explanation for the observed tumor cavitations and complications could be the relatively large primary tumor size in our patients, as 30% had a tumor measuring 8 cm or larger. A recent report suggests that many European centers consider tumors measuring more than 8 to 10 cm to be suitable for only palliative treatment. 17 Similarly, a recent European Organisation for Research and Treatment of Cancer (EORTC) study excluded patients if the tumor volume required a radiation field encompassing 12 cm or more of the esophagus in the high-dose region.
High-dose radiotherapy may contribute to tumor cavitation because of radiationinduced decreases in regional lung perfusion, 19 and central tumor necrosis has also been observed after two fractions of 18 Gy in patients undergoing stereotactic radiotherapy.
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Although fluoro-2-deoxy-D-glucose positron emission tomography may also identify central tumor necrosis, baseline tumor cavitation identified on fluoro-2-deoxy-D-glucose positron emission tomography has not been shown to be a poor prognostic feature. 21 However, it should be pointed out that patients in the last mentioned report did not undergo CCRT.
A study of transthoracic aspirates from cavitating tumors showed that six of seven febrile patients had positive aspiration cultures at diagnosis. 22 Since 2009, cone-beam CT scans are routinely performed during the course of radiotherapy at our center, and this can potentially facilitate the earlier detection of tumor cavitation and/or abscess during CCRT.
Early identification of tumor cavitation may indicate a need for treatment using appropriate antibiotics. Surgical management of lung abscess has been previously described in 247
patients, excluding abscesses secondary to carcinoma. 23 Despite conservative treatment in all, 119 and 58 patients underwent subsequent surgical drainage or pulmonary resection, Some limitations of the present study must be recognized, one of which is the fact that it is restricted to patients in whom all follow-up was performed within the VU University Medical Center. Although overall survival between patients with or without tumor cavitation was not significantly different in this relatively small study, our findings suggest caution when using CCRT in this setting.
We postulate that primary surgical resection with postadjuvant chemoradiotherapy in patients who are potentially resectable could be a strategy to prevent complications of tumor cavitation. In addition, administration of weekly low-dose chemotherapy is potentially a less toxic alternative. Finally, evidence of infection in a developing cavity requires aggressive antibiotic treatment and probably early surgical intervention.
